Caribou Biosciences (CRBU) Citi’s 2026 Virtual Oncology Leadership Summit summary

Conference overview

• Virtual Oncology Summit 2026 featured fireside chats and one-on-ones with biotech leaders, focusing on next-generation therapies for cancer treatment.

• Key sessions included discussions on allogeneic CAR-T cell therapies and their transformative potential for broader patient access.

• Insights from both academic and community hospital physicians highlighted the need for off-the-shelf cell therapies.

• The summit emphasized the logistical and clinical barriers limiting current autologous CAR-T access.

• The event provided updates on pivotal clinical programs and future trial designs.

Technology and clinical program updates

• chRDNA CRISPR platform enables highly specific genome editing, advancing allogeneic CAR-T therapies.

• Vispa-cel, for large B cell lymphoma, showed phase I results on par with autologous CAR-Ts and is now pivotal-ready.

• CB-011, targeting multiple myeloma, demonstrated response rates exceeding bispecific antibodies in early trials.

• Both programs leverage learnings on donor age and HLA matching to optimize outcomes.

• Ongoing dose expansion and longer-term follow-up data are expected this year.

Market need and access

• Only 25% of large B cell lymphoma and 10% of myeloma patients currently access auto CAR-Ts due to speed and geography.

• Allogeneic CAR-Ts could address the majority of patients who cannot access current therapies.

• Community hospitals are eager to participate in pivotal studies and future commercial launches.

• Off-the-shelf therapies could transform care by enabling broader, faster access.

• Commercial opportunity is significant, with physician discretion expected to drive adoption.